Related Experiment Video

Updated: Sep 12, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Paediatric myelodysplasia

S J Passmore1, I M Hann

  • 1Department of Haematology and Oncology, Great Ormond Street Children's Hospital, London, UK.

British Medical Bulletin
|October 1, 1996
PubMed

Insights

Childhood myelodysplastic syndromes (MDS) are diverse. Bone marrow transplant (BMT) offers a cure for many, but some MDS types require tailored treatment. Prognosis improves with matched sibling BMT and unrelated donor BMT availability.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Childhood myelodysplastic syndromes (MDS) represent a varied group of pediatric hematologic disorders.
  • Many pediatric MDS cases exhibit resistance to conventional intensive chemotherapy regimens.
  • Bone marrow transplant (BMT) is currently the sole curative option for numerous pediatric MDS patients.

Purpose of the Study:

  • To highlight the heterogeneity within pediatric myelodysplastic syndromes.
  • To emphasize the necessity of differentiating indolent MDS types for appropriate treatment.
  • To discuss the evolving role and improving outcomes of BMT in treating childhood MDS.

Main Methods:

  • Review of existing literature on pediatric myelodysplastic syndromes.
  • Analysis of treatment responses and outcomes, particularly concerning chemotherapy and BMT.
  • Comparative assessment of matched sibling BMT versus unrelated donor BMT efficacy.

Main Results:

  • Pediatric MDS is not a monolithic entity; distinct subtypes exist with varying clinical courses.
  • Certain pediatric MDS subtypes follow a more indolent progression, necessitating individualized therapeutic strategies.
  • Outcomes for children undergoing matched sibling BMT for MDS are progressively improving.

Conclusions:

  • Accurate classification of pediatric MDS subtypes is crucial for optimizing patient management.
  • Bone marrow transplant (BMT) is a vital curative treatment for childhood MDS, with expanding accessibility through unrelated donors.
  • Continued advancements in BMT techniques and donor availability are enhancing the long-term prognosis for pediatric MDS patients.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...